Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IMNM Stock 12 Month Forecast
Average Price Target
$24.90
▲(26.01% Upside)
| Highest Price Target$36.00 | Average Price Target$24.90 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Craig-Hallum
$26
Buy
31.58%
Upside
Reiterated
12/04/25
Truist Financial
$36
Buy
82.19%
Upside
Initiated
12/01/25
J.P. Morgan
$22
Buy
11.34%
Upside
Reiterated
11/30/25
Lake Street
$22
Buy
11.34%
Upside
Reiterated
11/18/25
Stephens
$25→$33
Buy
67.00%
Upside
Reiterated
11/17/25
TD Cowen
―
Buy
―
Reiterated
11/11/25
Immunome's Strategic Clinical Advancements and Financial Alignment Justify Buy RatingWe updated our model following Immunome's Q3 earnings report (note here). We slightly altered our expense estimates to be in alignment with the ongoing Phase III varegacestat trial and Phase I IM-1021 (ROR1 ADC) trial. We maintain our Buy rating.
Evercore ISI
$18
Buy
-8.91%
Downside
Reiterated
11/07/25
Piper Sandler
$21
Buy
6.28%
Upside
Reiterated
11/07/25
LifeSci Capital
$20
Buy
1.21%
Upside
Reiterated
11/06/25
Goldman Sachs
$26
Buy
31.58%
Upside
Initiated
09/22/25
Immunome's Promising Oncology Pipeline and Strong Market Potential Justify Buy RatingImmunome Inc. (IMNM): A targeted oncology portfolio with best- and/or first-in- class potential; 2025 | 6:03AM EDT We initiate coverage on IMNM at Buy. IMNM is a clinical stage biotechnology company developing in-house and acquired potentially best- and/or first-in-class targeted oncology therapeutics. IMNM's most advanced asset, varegacestat, a gamma-secretase inhibitor, is currently being investigated in the Ph3 RINGSIDE study in patients with desmoid tumors, with data expected at YE25.
Leerink Partners
―
Buy
―
Reiterated
09/19/25
Leerink Partners Keeps Their Buy Rating on Immunome (IMNM)We think this continues to support IMNM's expanding toolbox of antibodies for their ADC pipeline development. These developments are important as the 2H Ph 3 data readout out evaluating the gamma secretase varegacestat in desmoid tumors is expected by YE, and the focus shifts to the company's ADC platform that is a key interest for many investors.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
$26
Buy
31.58%
Upside
Reiterated
12/04/25
Truist Financial
$36
Buy
82.19%
Upside
Initiated
12/01/25
J.P. Morgan
$22
Buy
11.34%
Upside
Reiterated
11/30/25
Lake Street
$22
Buy
11.34%
Upside
Reiterated
11/18/25
Stephens
$25→$33
Buy
67.00%
Upside
Reiterated
11/17/25
TD Cowen
―
Buy
―
Reiterated
11/11/25
Immunome's Strategic Clinical Advancements and Financial Alignment Justify Buy RatingWe updated our model following Immunome's Q3 earnings report (note here). We slightly altered our expense estimates to be in alignment with the ongoing Phase III varegacestat trial and Phase I IM-1021 (ROR1 ADC) trial. We maintain our Buy rating.
Evercore ISI
$18
Buy
-8.91%
Downside
Reiterated
11/07/25
Piper Sandler
$21
Buy
6.28%
Upside
Reiterated
11/07/25
LifeSci Capital
$20
Buy
1.21%
Upside
Reiterated
11/06/25
Goldman Sachs
$26
Buy
31.58%
Upside
Initiated
09/22/25
Immunome's Promising Oncology Pipeline and Strong Market Potential Justify Buy RatingImmunome Inc. (IMNM): A targeted oncology portfolio with best- and/or first-in- class potential; 2025 | 6:03AM EDT We initiate coverage on IMNM at Buy. IMNM is a clinical stage biotechnology company developing in-house and acquired potentially best- and/or first-in-class targeted oncology therapeutics. IMNM's most advanced asset, varegacestat, a gamma-secretase inhibitor, is currently being investigated in the Ph3 RINGSIDE study in patients with desmoid tumors, with data expected at YE25.
Leerink Partners
―
Buy
―
Reiterated
09/19/25
Leerink Partners Keeps Their Buy Rating on Immunome (IMNM)We think this continues to support IMNM's expanding toolbox of antibodies for their ADC pipeline development. These developments are important as the 2H Ph 3 data readout out evaluating the gamma secretase varegacestat in desmoid tumors is expected by YE, and the focus shifts to the company's ADC platform that is a key interest for many investors.
Best Analysts Covering Immunome
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+8.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +8.54% per trade.
3 Months
xxx
Success Rate
5/5 ratings generated profit
Average Return
+30.38%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +30.38% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+86.86%
reiterated a buy rating last month
Copying Charles Zhu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +86.86% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+86.86%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IMNM Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
13
16
17
8
4
Buy
1
2
4
10
10
Hold
11
16
10
9
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
34
31
27
18
Each month's total comprises the sum of three months' worth of ratings.
IMNM Financial Forecast
IMNM Stock Forecast FAQ
What is IMNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunome’s 12-month average price target is 24.90.
What is IMNM’s upside potential, based on the analysts’ average price target?
Immunome has 26.01% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IMNM a Buy, Sell or Hold?
Immunome has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Immunome’s price target?
The average price target for Immunome is 24.90. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $18.00. The average price target represents 26.01% Increase from the current price of $19.76.
The highest analyst price target is $36.00 ,the lowest forecast is $18.00. The average price target represents 26.01% Increase from the current price of $19.76.
What do analysts say about Immunome?
Immunome’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of IMNM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.